Journals / Viral Hepatitis Journal / 2014 / Cilt: 20 - Sayı: 3

2005-2013 Yılları Arasında Hastanemize Başvuran Hastalarda HBsAg, Anti-Hepatit C Virüsü ve Anti-HIV Seroprevalansı

HBsAg, Anti-Hepatitis C Virus and Anti-HIV Seroprevalence Among Patients Admitted to Our Hospital between 2005 and 2013

Pages
125–130
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Our HBsAg positivity rate was relatively low whereas anti-HIV and anti-HCV results were found to be similar with the country statistical data.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV infections constitute a major health problem in our country as is in the world.
📊
Key Findings & Data:This study intended to determine the distribution of the seropositivity rates for HBsAg, anti- HCV, and anti-HIV according to genders, age groups, and years in patients admitted to our hospital.
💡
Conclusion & Impact:Conclusion: Our HBsAg positivity rate was relatively low whereas anti-HIV and anti-HCV results were found to be similar with the country statistical data.
🔬Design:Research Article
📍Scope:2005 Verileri
⚙️Variables:Domain Parameters

Abstract

Objectives: Hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV infections constitute a major health problem in our country as is in the world. This study intended to determine the distribution of the seropositivity rates for HBsAg, anti- HCV, and anti-HIV according to genders, age groups, and years in patients admitted to our hospital. Materials and Methods: We retrospectively analyzed HBsAg, anti-HCV, and anti-HIV test results in patients admitted to our hospital between June 2005 and December 2013. The tests were conducted using the methods of chemiluminescent microparticle immunoassay (Architect i 1000, Abbott, USA), chemiluminescent immunoassay (Vitros ECI Q, Ortho Clinical Diagnostics, USA, ADVIA Centaur Bayer- Siemens, Germany), and electro-chemiluminescence immunoassay (Cobas 6000, Roche Diagnostic GmbH, Germany). Results: The seropositivity rates and the number of the samples studied were as follows: HBsAg was found in 3.379 out of 152608 patients (2.21%), anti-HCV in 877 out of 155.585 patients (0.56%) and anti-HIV in one out of 125.084 patients (0.0008%). Positivity rate distribution by gender was determined as 39.42% of females and 60.58% of males for HBsAg; 53.48% of females and 46.52% of males for anti-HCV. The only sample found to be positive in anti-HIV test belongs to a female patient. Conclusion: Our HBsAg positivity rate was relatively low whereas anti-HIV and anti-HCV results were found to be similar with the country statistical data.

Özet

Amaç: Dünyada olduğu gibi ülkemizde de hepatit B virüsü (HBV), hepatit C virüsü (HCV) ve HIV enfeksiyonları önemli bir sağlık sorunu oluşturmaktadır. Bu çalışmada hastanemize başvuran hastalarda HBsAg, anti-HCV ve anti-HIV seropozitiflik oranlarının yıllara, cinsiyetlere ve yaş gruplarına göre dağılımlarını belirlemeyi amaçladık. Gereç ve Yöntemler: Haziran 2005-Aralık 2013 tarihleri arasında hastanemize başvuran hastalarda HBsAg, anti-HCV ve anti-HIV test sonuçları geriye dönük olarak incelenmiştir. Testler kemilüminesans mikropartikül immunoassay (Architect i 1000, Abbott, USA), kemilüminesans immünassay (Vitros ECİ Q, Ortho Clinical Diagnostics, USA, Advia Centaur XP Bayer-Simens, Germany) ve elektrokemilüminesans immünoassay (Cobas 6000, Roche Diagnostic GmbH, Germany) yöntemleri ile çalışılmıştır. Bulgular: Çalışılan örnek sayıları ve seropozitiflik oranları; HbsAg 152,608 hastada 3379 (%2,21), anti HCV 155,585 hastada 877 (%0,56) ve anti HIV 125084 hastada bir (%0,0008) olarak bulunmuştur. Pozitiflik oranlarının cinsiyetler göre dağılımlar; HBsAg için %39,42 kadın, %60,58 erkek, anti-HCV için %53,48 kadın, %46,52 erkek olarak tespit edilmiştir. Anti-HIV testinde pozitif bulunan tek örnek kadın hastaya aittir. Sonuç: HBsAg pozitiflik oranımız genel olarak ülke verilerine göre düşük, anti-HIV ve anti-HCV sonuçlarımız ise ülke verileri ile benzer bulunmuştur.

🔖

Cite This Article

AVCIKÜÇÜK, H., SÜZÜK, S., KAVAK, M. (2014). 2005-2013 Yılları Arasında Hastanemize Başvuran Hastalarda HBsAg, Anti-Hepatit C Virüsü ve Anti-HIV Seroprevalansı. Viral Hepatitis Journal, Cilt: 20 - Sayı: 3, 125–130. https://ajindex.com/articles/332733

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Scott JD, Gretch DR. hepatitis C and G viruses. (abacıoğlu h Trans.). Başustaoğlu a (ed.). Clinical Microbiology 9. edition. ankara: atlas Publishing. 2009:1437-1452. 2. horvat RT, Tegtmeier Ge. hepatitis B and D viruses. (İyigün CP, avcı İY Trans.). Başustaoğlu a (ed.) Clinical Microbiology 9. edition. ankara: atlas Publishing. 2009:1641-1659. 3. kantarceken B. Chronic hepatitis hepatitis B-natural Progress. http://www.vhsd.org/files/file/2009_sunumlar/ 1.pdf, access date: 24.03.2014
  2. Tosun S. The Changing viral hepatitis epidemiology in our Country. ankeM Journ. 2013; 27 (2): 128-134
  3. Gökengin D. epidemiological Status of Sexually Transmitted Diseases. ankeM Journ. 2012; 26 (2): 186-188. 6. özdemir D, kurt h. epidemiology of hepatitis B virus Infections. Tabak F, Balık İ, Tekeli e (ed.). viral hepatitis 2007. İstanbul: viral hepatitis Prevention Society. 2007; 108-117
  4. Demir İ, kaya S, Demirci M, Cicioğlu-arıdoğan B. hepatitis B virus seropositivity investigation on Isparta Province health Professionals. Journal of Infection. 2006; 20 (3): 183-187
  5. Tözün n, özdoğan o, Çakaloğlu Y, İdilman R, karasu z, akarca u, et al. a nationwide Prevalence Study and Risk Factors for hepatitis a, B, C and D Infections in Turkey, the 61st annual Meeting of the american association for the Study of liver Diseases: The liver Meeting® 2010. october 29 november 2 2010, Boston uSa, Poster no: 789, hepatology vol. 52 S1: 697. 9. ulutürk R. 11-year evaluation of Routine Screening Tests in Blood Donors. Turkish Microbiology Society Journal. 2010; 40(1): 41-47. 10. altındiş M, aslan S, kalaycı R. hBsag, anti-hCv, anti-hIv and Syphilis Seroprevalence in Blood Donors. Sakaryamj. 2011; 1: 22-26. 11. acar a, kemahli S, altunay h, kosan e, oncul o, Gorenek l, Cavuslu S. hBv, hCv and hIv Seroprevalence among Blood Donors in Istanbul, Turkey: how effective are the Changes in the national Blood Transfusion Policies? Braz J Infect Dis. 2010; 14(1): 41-46
  6. Patel S, Popat C, Mazumdar v, Shah M, Shringarpure k, Mehta kG, et al. Seroprevalence of hIv, hBv, hCv and Syphilis in Blood Donors at a Tertiary hospital (blood bank) in vadodara. Int J Med Sci Public health. 2013; 2(3): 747-50
  7. Jain C, Mogra nC, Mehta J, Diwan R, Dalela G. Comparison of seropositivity of hIv, hBv, hCv, and Syphilis and Malaria in Replacement and voluntary Blood Donors in Western India. Int J Cur Res Rev. 2013; 5(3): 43-46
  8. Thaker Mv, Shah Ph, Gosalia vv, valiya lG, Suri Sk. Seroprevalence of